• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Orion

66.60 EUR

-2.56 %

14,415 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-2.56 %
-1.11 %
-4.10 %
+4.63 %
+10.91 %
+5.21 %
+68.69 %
+75.59 %
+493.05 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
9.4B EUR
Turnover
11.99M EUR
P/E (adj.) (26e)
16.99
EV/EBIT (adj.) (26e)
13.23
P/B (26e)
5.89
EV/S (26e)
4.5
Dividend yield-% (26e)
2.68 %
Coverage
Recommendation
Buy
Target price
80.00 EUR
Updated
23.04.2026
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.04.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Views on Orion’s share price can validly be presented within a fairly wide range. This €60 is fine, Inderes’s (Inden) €80 is fine, and the €100 presented by Erkki Sinkko in the media is also fine. This isn’t a bargain-bin stock, but cash is flowing in massively, all the company’s...
4/24/2026, 6:58 AM
by PörssiPatruuna
20
Well, why not! It took the competing TEAD inhibitor VT3989 ~5 years to get from the start of the clinical program to the beginning of Phase 3. On this timeline, Orion’s Phase 3 could be completed by ~2034 and launch, for example, in 2035. In theory, of course, an accelerated marketing...
6/2/2026, 8:15 PM
by Antti Siltanen
12
Presenting results at ASCO does not guarantee brilliant results yet, but it does show that the findings are worthy of ASCO, which is a truly massive and significant event in oncology. Orion has already stated that ODM-212 showed clinical activity and tolerable safety in Phase 1, ...
5/21/2026, 9:24 AM
by Vino Pino
12
Here are Antti’s comments on the first results of Orion’s ODM-212 candidate Orion announced over the weekend preliminary results from the Phase I/II clinical trial of the cancer drug candidate ODM-212. Based on the results presented at the ASCO congress, the drug candidate has been...
6/1/2026, 5:51 AM
by Sijoittaja-alokas
11
Insights from the ASCO 2026 mega-cancer conference: a randomized “androgen inhibitor” comparison in prostate cancer, 111 patients, open-label phase 2. ascopost.com Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs... https://www.asco.org/abstracts-presentations...
6/3/2026, 8:08 AM
by Vino Pino
10
The ASCO abstract for the First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES) has been published: First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES). - ASCO As with other similar early-...
5/22/2026, 7:55 AM
by Vino Pino
10
Inderes Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta... ORION OYJ LEHDISTÖTIEDOTE 30.5.2026 KLO 21.30 Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla on kiinteitä kasvaimia...
5/30/2026, 6:51 PM
by Dissidentti
9
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7
2026

Interim report Q2'26

19.10
2026

Half year dividend

28.10
2026

Interim report Q3'26

Regulatory press release15 hours ago

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release6/11/2026, 2:00 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release6/10/2026, 3:10 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/5/2026, 2:00 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release6/1/2026, 11:00 AM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Orion: Første resultater fra lægemiddelkandidat ODM-212
Analyst Comment6/1/2026, 5:34 AM by
Antti Siltanen

Orion: Første resultater fra lægemiddelkandidat ODM-212

Fase I/II-studiet er allerede fortsat til næste del.

Orion
Press release5/30/2026, 6:30 PM

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Orion
Press release5/21/2026, 7:30 AM

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting

Orion
Regulatory press release5/15/2026, 6:00 AM

105,950 Orion Corporation A shares converted into B shares

Orion
Press release5/12/2026, 7:30 AM

Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Ari Lehtoranta

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Sophie Papa

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Minna Maasilta

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

Orion
Regulatory press release4/27/2026, 9:00 AM

Composition of the Nomination Committee of Orion Corporation

Orion
Orion Q1'26: Året starter med en stabil præstation
Research4/24/2026, 5:00 AM by
Antti Siltanen

Orion Q1'26: Året starter med en stabil præstation

Regnskabsmeddelelsen var på linje med vores forventninger.

Orion